These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 24524420)
21. Relationship between anti-Tax antibody responses and cocultivatable virus in HTLV-I-infected rabbits. Lydy SL; Conner ME; Marriott SJ Virology; 1998 Oct; 250(1):60-6. PubMed ID: 9770420 [TBL] [Abstract][Full Text] [Related]
22. Molecular mimicry: cross-reactive antibodies from patients with immune-mediated neurologic disease inhibit neuronal firing. Kalume F; Lee SM; Morcos Y; Callaway JC; Levin MC J Neurosci Res; 2004 Jul; 77(1):82-9. PubMed ID: 15197740 [TBL] [Abstract][Full Text] [Related]
23. Antibody-dependent cellular cytotoxicity and natural killer activity against HTLV-1 infected cells. Kunitomi T; Takigawa H; Sugita M; Nouno S; Suemune M; Inoue M; Kodani N; Oda M; Ikeda M Acta Paediatr Jpn; 1990 Feb; 32(1):16-9. PubMed ID: 2109484 [TBL] [Abstract][Full Text] [Related]
24. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Arnulf B; Thorel M; Poirot Y; Tamouza R; Boulanger E; Jaccard A; Oksenhendler E; Hermine O; Pique C Leukemia; 2004 Jan; 18(1):126-32. PubMed ID: 14574331 [TBL] [Abstract][Full Text] [Related]
25. Infection of human natural killer (NK) cells with replication-defective human T cell leukemia virus type I provirus. Increased proliferative capacity and prolonged survival of functionally competent NK cells. Lo KM; Vivier E; Rochet N; Dehni G; Levine H; Haseltine WA; Anderson P J Immunol; 1992 Dec; 149(12):4101-8. PubMed ID: 1460293 [TBL] [Abstract][Full Text] [Related]
26. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. Kubota R; Kawanishi T; Matsubara H; Manns A; Jacobson S J Immunol; 1998 Jul; 161(1):482-8. PubMed ID: 9647259 [TBL] [Abstract][Full Text] [Related]
27. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311 [TBL] [Abstract][Full Text] [Related]
28. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817 [TBL] [Abstract][Full Text] [Related]
29. Cross-neutralizing antibodies against cosmopolitan and Melanesian strains of human T cell leukemia/lymphotropic virus type I in sera from inhabitants of Africa and the Solomon Islands. Benson J; Tschachler E; Gessain A; Yanagihara R; Gallo RC; Franchini G AIDS Res Hum Retroviruses; 1994 Jan; 10(1):91-6. PubMed ID: 8179967 [TBL] [Abstract][Full Text] [Related]
30. Temporal dynamics of human T-lymphotropic virus type I tax mRNA and proviral DNA load in peripheral blood mononuclear cells of human T-lymphotropic virus type I-associated myelopathy patients. Ramirez E; Cartier L; Torres M; Barria M J Med Virol; 2007 Jun; 79(6):782-90. PubMed ID: 17457906 [TBL] [Abstract][Full Text] [Related]
32. Immune responses to HTLV-I(ACH) during acute infection of pig-tailed macaques. McGinn TM; Wei Q; Stallworth J; Fultz PN AIDS Res Hum Retroviruses; 2004 Apr; 20(4):443-56. PubMed ID: 15157363 [TBL] [Abstract][Full Text] [Related]
33. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders. Kozako T; Yoshimitsu M; Akimoto M; White Y; Matsushita K; Soeda S; Shimeno H; Kubota R; Izumo S; Arima N Hum Immunol; 2011 Nov; 72(11):1001-6. PubMed ID: 21851845 [TBL] [Abstract][Full Text] [Related]
34. Antibody-dependent cell-mediated cytotoxicity can protect PBMC from infection by cell-associated HIV-1. Hildreth JE; Hampton R; Halsey NA Clin Immunol; 1999 Feb; 90(2):203-12. PubMed ID: 10080832 [TBL] [Abstract][Full Text] [Related]
35. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells. Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954 [TBL] [Abstract][Full Text] [Related]
36. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I. Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182 [TBL] [Abstract][Full Text] [Related]
37. Human T-lymphotropic virus type I (HTLV-I)-specific CD8+ cells accumulate in the lungs of patients infected with HTLV-I with pulmonary involvement. Kawabata T; Higashimoto I; Takashima H; Izumo S; Kubota R J Med Virol; 2012 Jul; 84(7):1120-7. PubMed ID: 22585731 [TBL] [Abstract][Full Text] [Related]
38. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. Yamauchi J; Coler-Reilly A; Sato T; Araya N; Yagishita N; Ando H; Kunitomo Y; Takahashi K; Tanaka Y; Shibagaki Y; Nishioka K; Nakajima T; Hasegawa Y; Utsunomiya A; Kimura K; Yamano Y J Infect Dis; 2015 Jan; 211(2):238-48. PubMed ID: 25104771 [TBL] [Abstract][Full Text] [Related]
39. Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras. Hadlock KG; Yang Q; Rowe J; Foung SK AIDS Res Hum Retroviruses; 2002 Jan; 18(1):57-70. PubMed ID: 11804557 [TBL] [Abstract][Full Text] [Related]
40. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells. Chung S; Lin YL; Reed C; Ng C; Cheng ZJ; Malavasi F; Yang J; Quarmby V; Song A J Immunol Methods; 2014 May; 407():63-75. PubMed ID: 24704820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]